Virus-like particle (VLP) technology is a promising approach for the construction of novel
vaccines, diagnostic tools, and gene therapy vectors. Initially, VLPs were primarily derived …

A dengue vaccine should induce long-lasting, simultaneous protection to the four dengue
viruses while avoiding the immune enhancement of viral infection. Domain III of the dengue …

Dengue virus (DENV) induces strong T and B cell responses upon infection. Hence, it is
difficult to determine the contribution of cell-mediated immunity alone in the long lasting …

Recent worldwide outbreaks of Zika virus (ZIKV) infection and the lack of an approved
vaccine raise serious concerns regarding preparedness to combat this emerging virus. We …

The development of virus-like particle (VLP) based vaccines for human papillomavirus,
hepatitis B and hepatitis E viruses represented a breakthrough in vaccine development …

Dengue infection is a major cause of morbidity in tropical and subtropical regions, bringing
nearly 40% of the world population at risk and causing more than 20,000 deaths per year …

Since the beginning of the COVID-19 pandemic, the development of effective vaccines
against this pathogen has been a priority for the scientific community. Several strategies …

Based on the immunogenicity of domain III from the Envelope protein of dengue virus as
well as the proven protective capacity of the capsid antigen, we have designed a novel …

Transmitted by the Aedes aegypti mosquito, the dengue virus is the etiological agent of
dengue fever, dengue hemorrhagic fever and dengue shock syndrome, and, as such, is a …

The capsid protein is one of the three structural proteins of flaviviruses and is the building
block of the nucleocapsid. It has also a predominant role in the replication of dengue virus …